Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04190862 · ClinicalTrials.gov registry record · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
A Phase 1 study of Anal Fistula, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT04190862: Recruiting Phase 1 study of Anal Fistula, sponsored by Weill Medical College of Cornell University.
NCT04190862 is a Phase 1 study of Anal Fistula that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 39 participants, below the 294-participant average among 5 other Anal Fistula trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04190862, a Phase 1 study of Anal Fistula, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if endothelial cells derived from human umbilical vein are safe for use in conjunction with fistulotomy for the treatment of simple anal fistulas. Endothelial cells are a special kind of cell in the body that line the inside surface of blood vessels. The goal of the study is to evaluate the preliminary safety of human umbilical vein cells in anal fistula healing.
Primary Outcome
The short term safety of escalating dose of E-CEL UVEC cells in subjects with anal fistulas will be assessed by monitoring and recording all adverse events for 2 weeks following the administration of E-CEL UVEC. (Applicable to all arms)
Conditions Studied
Interventions
- DRUG E-CEL UVEC
Study Locations (1)
New York
- Weill Cornell Medical College - NewYork-Presbyterian Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2020-01-22 |
| Est. Completion | 2032-06-30 |
| Phase | Phase 1 |
What NCT04190862 shows while recruiting
NCT04190862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 294-participant average among 5 other Anal Fistula trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Anal Fistula appearing as the primary indexed condition, and to 1 intervention - of which E-CEL UVEC is the first listed.
NCT04190862 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04190862 about?
NCT04190862 is a clinical study titled "E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas". The purpose of this study is to determine if endothelial cells derived from human umbilical vein are safe for use in conjunction with fistulotomy for the treatment of simple anal fistulas. Endothelial cells are a special kind of cell in the body that line the inside surface of blood vessels. The goa...
What is the current status of trial NCT04190862?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2020-01-22. Estimated completion is 2032-06-30.
What conditions does trial NCT04190862 study?
This clinical trial studies the following conditions: Anal Fistula.
What interventions are being tested in trial NCT04190862?
The interventions under investigation include: E-CEL UVEC (DRUG).
Who is sponsoring clinical trial NCT04190862?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04190862 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anal Fistula
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BIOlogic Augmented Repair of Complex Anal Fistula Using Acellular Matrix and/or Autologous Platelet-rich Plasma
RECRUITING · NA
-
A Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02 For the Management of Anal Fistulas
RECRUITING · NA
-
Myriad™ Augmented Soft Tissue Reconstruction Registry
RECRUITING
-
Evaluating an rhPDGF-BB-enhanced Collagen Plug for Perianal Fistula Healing
ACTIVE NOT RECRUITING · Phase 2
-
Treatment of Perirectal Fistula With Cutting Seton vs. Collagen Plug
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04588545 · 39 participants · Phase 1
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI